TELA Bio Q2 EPS $(0.46) Beats $(0.53) Estimate, Sales $14.49M Beat $14.40M Estimate
Portfolio Pulse from Benzinga Newsdesk
TELA Bio reported Q2 earnings with losses of $(0.46) per share, beating the analyst consensus estimate of $(0.53) by 13.21%. This is a 47.73% increase over losses from the same period last year. The company also reported quarterly sales of $14.49 million, beating the estimate of $14.40 million by 0.65%, a 39.29% increase over sales from the same period last year.
August 09, 2023 | 8:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TELA Bio reported better than expected Q2 earnings and sales, indicating a positive financial performance.
TELA Bio's Q2 earnings and sales exceeded analyst estimates, which is likely to be viewed positively by investors and could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100